Literature DB >> 26717541

Obesity genes and risk of major depressive disorder in a multiethnic population: a cross-sectional study.

Zainab Samaan1,2,3, Yvonne K Lee, Hertzel C Gerstein, James C Engert, Jackie Bosch, Viswanathan Mohan, Rafael Diaz, Salim Yusuf, Sonia S Anand, David Meyre.   

Abstract

OBJECTIVE: Observational studies have shown a positive association between obesity (body mass index [BMI] ≥ 30 kg/m2) and depression. Around 120 obesity-associated loci have been identified, but genetic variants associated with depression remain elusive. Recently, our team reported that the fat mass and obesity-associated (FTO) gene rs9939609 obesity-risk variant is paradoxically inversely associated with the risk of depression. This finding raises the question as to whether other obesity-associated genetic variants are also associated with depression.
METHOD: Twenty-one obesity gene variants other than FTO were selected from a custom ∼50,000 single-nucleotide polymorphisms (SNPs) genotyping array (ITMAT-Broad-CARe array). Associations of these 21 SNPs and an unweighted genotype score with BMI and major depressive disorder (determined using the DSM-IV diagnostic criteria) were tested in 3,209 cases and 14,195 noncases, using baseline data collected from July 2001 to August 2003 from the multiethnic EpiDREAM study.
RESULTS: Body mass index was positively associated with depression status (odds ratio [OR] = 1.02; 95% CI, 1.02-1.03 per BMI unit; P = 2.9 × 10(-12), adjusted for age, sex, and ethnicity). Six of 21 genetic variants (rs1514176 [TNN13K], rs2206734 [CDKAL1], rs11671664 [GIPR], rs2984618 [TAL1], rs3824755 [NT5C2], and rs7903146 [TCF7L2]) and the genotype score were significantly associated with BMI (1.47 × 10(-14) ≤ P ≤ .04). Of the 21 SNPs, TAL1 rs2984618 obesity-risk allele was associated with a higher risk of major depressive disorder (P = 1.79 × 10(-4), adjusted for age, sex, BMI, and ethnicity), and BDNF rs1401635 demonstrated significant ethnic-dependent association with major depressive disorder (OR = 0.88; 95% CI, 0.80-0.97; P = .01 in non-Europeans and OR = 1.11; 95% CI, 1.02-1.20; P = .02 in Europeans; Pinteraction = 2.73 × 10(-4)). The genotype score, calculated with or without FTO rs9939609, and adjusted for the same covariates, was not associated with depression status.
CONCLUSIONS: Our data support the view that the association between obesity and major depressive disorder at the observational level may be explained, at least in part, by shared genetic factors. © Copyright 2015 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Year:  2015        PMID: 26717541     DOI: 10.4088/JCP.14m09720

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  12 in total

Review 1.  Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.

Authors:  Teodor T Postolache; Laura Del Bosque-Plata; Serge Jabbour; Michael Vergare; Rongling Wu; Claudia Gragnoli
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-02-06       Impact factor: 3.568

Review 2.  The genomic landscape of African populations in health and disease.

Authors:  Charles N Rotimi; Amy R Bentley; Ayo P Doumatey; Guanjie Chen; Daniel Shriner; Adebowale Adeyemo
Journal:  Hum Mol Genet       Date:  2017-10-01       Impact factor: 6.150

3.  The association of obesity and coronary artery disease genes with response to SSRIs treatment in major depression.

Authors:  Azmeraw T Amare; Klaus Oliver Schubert; Fasil Tekola-Ayele; Yi-Hsiang Hsu; Katrin Sangkuhl; Gregory Jenkins; Ryan M Whaley; Poulami Barman; Anthony Batzler; Russ B Altman; Volker Arolt; Jürgen Brockmöller; Chia-Hui Chen; Katharina Domschke; Daniel K Hall-Flavin; Chen-Jee Hong; Ari Illi; Yuan Ji; Olli Kampman; Toshihiko Kinoshita; Esa Leinonen; Ying-Jay Liou; Taisei Mushiroda; Shinpei Nonen; Michelle K Skime; Liewei Wang; Masaki Kato; Yu-Li Liu; Verayuth Praphanphoj; Julia C Stingl; William V Bobo; Shih-Jen Tsai; Michiaki Kubo; Teri E Klein; Richard M Weinshilboum; Joanna M Biernacka; Bernhard T Baune
Journal:  J Neural Transm (Vienna)       Date:  2019-01-04       Impact factor: 3.575

4.  Zinc Supplementation and Body Weight: A Systematic Review and Dose-Response Meta-analysis of Randomized Controlled Trials.

Authors:  Shima Abdollahi; Omid Toupchian; Ahmad Jayedi; David Meyre; Vivian Tam; Sepideh Soltani
Journal:  Adv Nutr       Date:  2020-03-01       Impact factor: 8.701

Review 5.  Expanding the clinical relevance of the 5'-nucleotidase cN-II/NT5C2.

Authors:  Lars Petter Jordheim
Journal:  Purinergic Signal       Date:  2018-10-25       Impact factor: 3.765

6.  Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study.

Authors:  Sophiya Garasia; Zainab Samaan; Hertzel C Gerstein; James C Engert; Viswanathan Mohan; Rafael Diaz; Sonia S Anand; David Meyre
Journal:  Sci Rep       Date:  2017-05-09       Impact factor: 4.379

7.  Pilot trial of a group cognitive behavioural therapy program for comorbid depression and obesity.

Authors:  Taryn Lores; Michael Musker; Kathryn Collins; Anne Burke; Seth W Perry; Ma-Li Wong; Julio Licinio
Journal:  BMC Psychol       Date:  2020-04-17

8.  Incidence of Depression and Associated Factors in Patients With Type 2 Diabetes in Quebec, Canada: A Population-Based Cohort Study.

Authors:  Carlotta Lunghi; Jocelyne Moisan; Jean-Pierre Grégoire; Line Guénette
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

Review 9.  The Trajectory from Mood to Obesity.

Authors:  Judith Wurtman; Richard Wurtman
Journal:  Curr Obes Rep       Date:  2018-03

10.  Childhood overweight and obesity and the risk of depression across the lifespan.

Authors:  Deborah Gibson-Smith; Thorhallur I Halldorsson; Mariska Bot; Ingeborg A Brouwer; Marjolein Visser; Inga Thorsdottir; Bryndis E Birgisdottir; Vilmundur Gudnason; Gudny Eiriksdottir; Lenore J Launer; Tamara B Harris; Ingibjorg Gunnarsdottir
Journal:  BMC Pediatr       Date:  2020-01-21       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.